Introduction
The expression of some early response genes is up-regulated by exposure to ionising radiation. [1] [2] [3] [4] [5] [6] [7] These genes include those encoding the human tissue-type plasminogen activator, tumour necrosis factor alpha (TNF-␣) and early growth response protein 1 (Egr1). 8, 9 Transcriptional activation of the Egr1 gene by ionising radiation appears to be a direct consequence of the production of reactive oxygen intermediates. 10 Although the precise activation mechanism has not been fully elucidated, 10 base pair sequences known as CArG elements have been identified as radio-responsive motifs within the Egr1 promoter, the majority of which are positioned within serum response elements. 9, 10 However, only the CArG elements groupedcould be repeated by additional radiation treatments. The latter indicates that up-regulation should be additive during fractionated radiotherapy schedules. To demonstrate the potential clinical benefit of such an approach, the synthetic promoters were also shown to drive expression of the herpes simplex virus thymidine kinase gene, leading to enhanced cell killing in the presence of the prodrug ganciclovir (GCV) when compared with cells treated with radiation alone. Our results demonstrate that the synthetic promoter is responsive to low doses of ionising radiation and therefore isolated CArG elements function as radiation-mediated transcriptional enhancers outside their normal sequence context. The continued development and optimisation of such radiation-responsive synthetic promoters is expected to make a valuable contribution to the development of future radiation-responsive vectors for cancer gene therapy. Gene Therapy (2000) 7, 511-517.
The radiation inducibility of the Egr1 promoter has been exploited in several experimental gene therapy strategies. Joki et al 11 and Takahashi et al 12 used a plasmid construct containing Egr1 gene sequences (positions −425 to +65 within the wild-type promoter) containing six CArG elements (first described in Gius et al 13 ), in combination with the herpes simplex virus thymidine kinase (HSVtk) gene. Glioma cells containing this vector were sensitised to the antiviral agent ganciclovir (GCV), a substrate for HSVtk, after exposure to a single radiation dose of 20 Gy. 11 Direct intra-tumoural injection has also been used to deliver an adenovirus vector containing Egr1 enhancer-controlled TNF-␣ gene to human epithelia SQ-20B tumour xenografts. 14, 15 In these studies a radiation dose schedule of 40 Gy, given as 5 Gy fractions twice a day for 4 days, increased tumour regression by up to 90% of control values compared with maxima of 50% for vector or radiation alone.
14 Similar results were obtained using a murine fibrosarcoma model. 16 To date, there has been no evidence as to whether CArG elements will function independently of their natural sequence context, in which other potential regulatory regions such as putative binding sites for the transcription factors SP1 and AP-1 (tetra-decanoyl phorbol acetate or TPA responsive element), and the cAMP-responsive element binding protein are positioned. 17 In this study, we have investigated the potential of using isolated CArG elements as a model for the design of novel, synthetic radiation-responsive gene promoters, free from control of exogenous transcription factors. The development of a synthetic gene promoter has a number of attractions, both at the level of optimising radiation inducibility for future clinical use and also component minimisation, a feature particularly relevant for viral delivery owing to the vector size constraints imposed by some of these systems. Human MCF-7 breast adenocarcinoma and U87-MG glioma cells transfected with plasmids containing the green fluorescent protein (GFP) coding sequence, under the control of the synthetic promoter, were irradiated and GFP expression measured. Our results demonstrate that a series of four directly repeated CArG elements are able to function as radio-responsive transcriptional enhancers in reporter gene assays and inhibit cell growth when driving HSVtk production in combination with GCV. Furthermore, the synthetic enhancer showed a significantly higher level of radiation inducibility than the wild-type human Egr1 enhancer in MCF-7 cells.
Results
Flow activated cell sorter (FACS) analysis was used to quantify GFP gene expression. This method was used to measure the number of cells that fluoresced above a specific intensity threshold 40 h after transfection with plasmids carrying the GFP reporter gene (see Materials and methods) under the control of the different test promoters. Figure 1 compares the radiation inducibility of . A marginal increase (MCF-7; 1.26-fold ± 0.14: U87-MG; 1.15-fold ± 0.11) in CMV promoter-mediated GFP expression was also observed after irradiation (pCGFP; Figure 1 ), albeit at a significantly reduced level compared with the other two promoters (P Ͻ 0.05 Student's t test).
Having demonstrated that the synthetic gene promoter was radiation responsive, the effect of varying the size of the inducing dose of radiation on the level of reporter gene expression was investigated (Figure 2 ). In these experiments, it was evident that the level of gene expression observed was dependent on radiation dose, with maximal expression seen after 3 Gy for both U87-MG (1.62 ± 0.14-fold) and MCF-7 (2.17 ± 0.19-fold) cells. In U87-MG cells, triggering doses at 2-5 Gy produced significantly higher levels of induction than either 1 or 10 Gy (P Ͻ 0.05, Duncan's multiple range test). Although the same pattern of induction was seen for MCF-7 cells, the difference in expression at 2-5 Gy and 1 or 10 Gy did not reach statistical significance (P = 0.24). However, in
Figure 2 Fold increase of GFP expression in U87-MG and MCF-7 cells 40 h after pE4GFP transfection and irradiation with a range of radiation doses. The bars represent data from three independent experiments (± s.d.) each containing a minimum of two replicates.
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Figure 3 Fold increase of GFP expression in U87-MG and MCF-7 cells 40 h after pE4GFP transfection and irradiation with single or fractionated doses (12-h interval). The bars represent data from three independent experiments (± s.d.) each containing a minimum of two replicates.
Figure 4 Effect of radiation on growth of MCF-7 cells exposed to various transfection treatments. The data points represent a minimum of at least two independent experiments each consisting of 48 replicates per dose point, error bars are standard deviation. Open squares, MCF-7 cells; open triangles, MCF-7 cells transiently transfected with the control plasmid pCon; solid squares, MCF-7 cells transiently transfected with pE4TK plasmid; open circles, MCF-7/E4TK novel cell line.
both cell lines the synthetic promoter was activated after treatment with radiation doses as low as 1 Gy.
Patient treatments with radiation are given as small, fractionated doses, therefore the effect of multiple, low doses of radiation on the inducibility of the system was also examined (Figure 3 ). The higher level of reporter Gene Therapy gene expression seen after five 1 Gy radiation treatments administered at 12-h intervals compared with that after a single dose of 1 Gy, indicated that the inducibility of the synthetic promoter was temporal and could be repeatedly reactivated using a clinically relevant fractionation schedule. Indeed, a similar level of reporter gene expression was seen after five doses of 1 Gy compared with a single dose of 5 Gy for both U87-MG (P = 0.40 Student's t test) and MCF-7 (P = 0.24 Student's t test) cells. Whereas, a significant increase in gene expression was observed when two fractions of 5 Gy separated by a 12-h interval were given compared with a single dose of 10 Gy, for both U87-MG (P Ͻ 0.01, Student's t test) cells and MCF-7 (P Ͻ 0.05 Student's t test) cells.
A plasmid was then constructed in which the GFP ORF (open reading frame) in the pE4GFP plasmid was replaced with the HSVtk ORF (to give pE4TK). The growth delay of pE4TK plasmid-transfected MCF-7 cells was then measured in the presence and absence of a nontoxic concentration of the prodrug ganciclovir (GCV; 50 m) (Figure 4 ). In addition, growth was also measured in a novel cell line (MCF-7/E4TK; in which HSVtk gene expression was regulated by the synthetic promoter) established by transfection of MCF-7 cells with pE4TK and subsequent clonal selection in neomycin (see Materials and methods). A significant increase in growth inhibition was seen with increasing radiation dose (P Ͻ 0.001; two-way analysis of variance allowing for dose) for the novel cell line (MCF-7/E4TK). For example, a ෂ45% increase at 3 Gy, the dose previously giving maximal synthetic enhancer activation, compared with that seen for MCF-7 parental cells. As would be predicted, a smaller, but significant growth inhibition (P Ͻ 0.014; two-way analysis of variance allowing for dose) was also seen for MCF-7 cells transiently transfected with pE4TK plasmids containing the HSVtk ORF under the control of the synthetic radiation responsive enhancer compared with untransfected parental MCF-7 cells over the 1-5 Gy dose range. No growth inhibition was seen when cells were transfected with a control plasmid (pCon) lacking the TK ORF.
Discussion
The Egr1 promoter is known to be transiently activated by ionising radiation. 5, 6, 14 The radio-responsive enhancer, containing four 'CArG' elements, has been identified in the 5Ј distal region of the Egr1 promoter. 9, 10 In the current study, this Egr1 enhancer (in the plasmid pNGFP) was found to induce a 1.67-fold increase in reporter gene expression in MCF-7 cells after a single radiation dose of 5 Gy (Figure 1 ). In the same experiments our synthetic enhancer, consisting solely of four directly repeated CArG elements (E4; in the pE4GFP plasmid) showed a significantly greater activation at the same dose (1.99-fold) in MCF-7 cells.
Using the Egr1 enhancer Weichselbaum et al 6 reported a 3.2-fold induction in chloramphenicol acetyltransferase (CAT) reporter gene expression in human HL252 cells in vitro and a 2.7-fold induction in SQ-20B tumour xenografts after a single 20 Gy treatment. These values compare favourably with an average induction for our synthetic enhancer (containing four CArG elements) of 1.77-fold after the considerably smaller dose of 5 Gy and 2.17-fold after only 3 Gy in MCF-7 cells as determined by our GFP expression assay (Figure 2) . A similar dose response pattern was also seen for U87-MG cells, albeit with a marginally lower level of induced GFP expression (Figure 2) . Interestingly, in a study of four different glioma cell lines Joki et al 11 reported a two-to 10-fold variation in Egr1 enhancer induction after a single dose of 20 Gy. In their study, the lowest level of expression (two-fold) was seen for U87-MG cells, which is comparable to the data in Figure Figure 2) .
The difference in the levels of GFP expression seen between U87-MG and MCF-7 cells in our studies is also likely to be cell type dependent and not reflective of plasmid transfection efficiency, since fold-induction values are calculated by normalisation against unirradiated transfected controls (see Materials and methods). For both cell lines, increasing the size of the radiation dose did not always produce greater levels of reporter gene expression (Figure 2) . Increasing the size of the inducing signal from 1-3 Gy increased the activation of GFP, but a further increase to 10 Gy decreased expression. The reason for the decrease in gene induction for 5 and 10 Gy is unknown but possibly reflects the choice of GFP as the reporter system since cells must remain viable for FACS scoring. In support of this, fractionating the treatment to give the same total dose (2 × 5 Gy compared with a single 10 Gy dose; 5 × 1 Gy compared with 5 Gy) lead to increased levels of GFP expression in both U87-MG and MCF-7 cells. These data indicate that the synthetic promoter can be repeatedly reactivated by fractionated radiation dosing, a factor which would be important in achieving high levels of therapeutic gene expression in the clinical setting. Furthermore, multiple administration of a gene therapy vector containing Egr1 enhancer-controlled TNF-␣ has been shown to enhance tumour killing above that seen after a single vector administration using the same radiation dosing schedule. 18 This suggests that combining fractionated radiation treatment with multiple administration of a re-inducible vector may give greater levels of efficacy than individual treatments.
As the synthetic promoter was shown to be more inducible than the wild-type Egr1 enhancer in MCF-7 cells it is therefore reasonable to suggest that CArG elements can respond better to radiation-induction when outside their normal sequence context. In these cell lines, this may reflect the deregulation of expression from other transcription factors with binding sites in the promoter region. These regions include binding sites for SP1 transcription factor, AP-1 (TPA responsive element), cAMP responsive element binding protein and Egr1 itself. 17 The absence of such regulatory sites in the synthetic promoters may therefore prove to be advantageous in maximising gene expression in future therapeutic vectors. Moreover, such a hypothesis would suggest that the inducibility of the synthetic promoter may be further increased by the inclusion of more CArG elements.
The efficacy of the radiation inducibility of the synthetic promoter to drive prodrug killing of tumour cells was demonstrated in growth inhibition experiments using HSVtk and the prodrug GCV ( Figure 4 ). As expected, transfection of MCF-7 cells with a control plasmid lacking the HSVtk gene (pCon) did not inhibit cell growth in the presence of GCV. However, a significant increase in growth inhibition was seen when MCF-7 cells were transiently transfected with pE4TK (P = 0.014). For example, a 12% increase in growth inhibition was seen after a clinically relevant dose of 2 Gy. This would translate into the equivalent of an additional 10 Gy of radiation damage being localised in the tumour assuming a standard radiotherapy schedule of 35 fractions of 2 Gy. This extrapolation is dependent on 20% of the tumour cells expressing the radio-responsive vector (based on our average transfection efficiency) and a two-fold induction of the therapeutic gene being achieved after each radiation dose fraction. The greater enhancement in growth inhibition for the MCF-7/E4TK novel cell line (Figure 4) indicates the potential efficiency of this system if the majority of tumour cells expressed the construct.
Ganciclovir (GCV) exhibits a bystander killing effect, whereby the phosphorylated drug is passed from producer cells, primarily by gap junctions, to kill non-producing neighbouring cells. 19 The killing seen when only a proportion of the tumour cells contain the construct could be increased by using more metabolically stable prodrugs which elicit better bystander effects, 20,21 reducing the need to express the gene in the majority of tumour cells. We predict that the increased metabolic stability of various novel nucleoside pro-drugs will also have a marked effect on the efficacy of HSVtk-mediated tumour cell killing, by ensuring the longer term presence of substrate.
We are unaware of any evidence for radiation responsive elements in the CMV IE promoter, yet when this vector was transfected an increase in GFP expression was seen following treatment with a 5 Gy dose of radiation ( Figure 1 ). The most likely explanation for this is the incorporation of the plasmid into genomic DNA at sites of radiation-induced damage, rather than true radiationinduced promoter activation. Such events would allow integrated plasmids to be transferred to daughter cells following subsequent cell division and as the CMV promoter is constitutive, these progeny cells would also fluoresce. This hypothesis is supported by the data of Stevens et al, 22 which show exposure to ionising radiation substantially increases transfection efficiency in human cells by mediating plasmid integration into cellular DNA. This finding may prove particularly useful for radiationmediated cancer gene therapy, where any surviving tumour cells bearing incorporated therapeutic genes carried on plasmid vectors would retain them following cell division, and thus progeny cells would also be therapeutic targets. In addition, the combination of radiation and 'suicide' gene therapy has been shown to enhance tumour cell killing, even when the therapeutic gene is controlled by a non-radiation-inducible promoter such as CMV IE. 23 Many groups have been exploring the means to obtain selective expression of genes in cancer cells as a strategy for tumour control. 24, 25 Limiting suicide gene expression to the tumour mass is extremely important if collateral damage to normal tissue is to be avoided. In radiationmediated gene therapy, expression of the therapeutic gene would be restricted to vector-containing tumour cells within the irradiated site. One advantage of our system is the potential to increase the effectiveness of the synthetic promoter (eg by increasing the number, arrangement and even sequence of CArG elements) in order to make it more responsive to the size of the radiation doses used in current radiotherapy regimes. Lowering the radiation dose threshold for promoter activation would also be clinically advantageous particularly in the treatment of highly radiosensitive individuals who exhibit severe reactions to current clinical dose regimes. Finally, the adoption of smaller synthetic promoters would allow larger therapeutic gene constructs to be used. This would be of particular benefit where viral delivery vectors are employed where there is a limited size capacity for foreign DNA. Thus the continued optimisation of radiation-responsive synthetic promoters is expected to make a valuable contribution to the development of future vectors for cancer gene therapy.
Materials and methods
Cell culture Human MCF-7 breast adenocarcinoma (ATCC HTB 22) and U87-MG glioblastoma-astrocytoma (ATCC HTB-14) cell lines were obtained from American Tissue Type Culture Collection. Both cell lines were maintained in monolayer culture in complete medium comprising RPMI 1640 culture medium supplemented with 10% foetal calf serum (FCS) (Biological Industries, Kibbutz Bet Haemek, Israel) and l-glutamine (2 mm). All media and supplements were obtained from GibcoBRL, Paisley, UK. Cells were maintained as monolayers at 37°C in vented T25 tissue culture flasks (Falcon) containing 5 ml of complete medium in a water-saturated atmosphere of 95% air:5% CO 2 throughout. Subculturing occurred weekly (seeded at 5 × 10 5 cells/ml), plus twice-weekly feeding with complete medium.
Construction of plasmids
The pCIneo plasmid (GibcoBRL) was used as the basis for all the vector constructs. The 'enhanced' GFP open reading frame was excised from the pEGFP-1 plasmid (Clontech, Basingstoke, UK) and cloned as an EcoRI/NotI fragment into the corresponding sites in pCIneo (creating pCGFP). The Egr1 enhancer was cloned as a 550 base pair (bp) PCR product derived from purified HeLa DNA using the primers: 5Ј-TCCAGATCTCAGCCGCTCC TCCCCCGCAC-3Ј and 5Ј-ACTGCGATCGCGGGCCCGG CCCGGCCCGCATCC-3Ј (synthesised by GibcoBRL) representing the −695 to −154 region of the natural promoter. 17 Amplification was performed for 10 cycles of 15 s at 94°C, 30 s at 50°C and 45 s at 72°C, with a further five cycles in which the elongation step was sequentially increased by 20 s each round. The expand Hi-Fidelity PCR System (Boehringer Mannheim, Lewes, UK) was used to minimise the introduction of mutations into the product. Synthetic enhancers containing four CArG elements were cloned as double-stranded linker molecules derived from complementary single-stranded oligonucleotides: 5Ј-GATCT(CCTTATTTGG) 4 CGAT-3Ј and 5Ј-A(GGAATAAACC) 4 CGC-3Ј. Linkers were produced by mixing 0.05 nmole of each oligonucleotide in 5 l volume, heating to 55°C for 5 min then cooling to room temperature. The enhancer region of the CMV IE gene promoter in pCGFP was replaced with the wild-type Egr1 enhancer (to produce pNGFP), or synthetic enhancer E4 (producing pE4GFP), using the BglII and SgfI sites at the linker ends. This created a chimaeric promoter consisting of an Egr1-derived enhancer and the basal CMV IE gene promoter containing the transcription start site and Gene Therapy TATA box. The HSVtk ORF was derived by PCR amplification from the original plasmid clone 26 using the primers 5Ј-GCTCTAGAGTCGACATGGCTTCGTACCCC GGC-3Ј and 5Ј-CCATCGATCTCCTTCCGTGTTTCAG TTAGC-3Ј. Amplification was performed as for the Egr1 enhancer using the following thermocyler program: 10 cycles of 15 s at 94°C, 30 s at 50°C and 60 s at 72°C, with a further five cycles in which the elongation step was sequentially increased by 20 s each round. The PCR product was then purified using a Nucleon PCR/Oligo Clean-Up kit (Immunogen International Ltd, Sunderland, UK), digested with XbaI/NotI and cloned into the corresponding sites in pE4GFP (replacing the GFP ORF and producing pE4TK). The Egr1 enhancer and HSVtk ORF was sequenced on both strands using the ABI Prism Kit and 373A Sequencer (Applied Biosciences, Warrington, UK) to verify the sequence integrity of the PCR product. Restriction endonucleases and modifying enzymes (MBI Fermentas, Sunderland, UK, and Promega, Southampton, UK) were used according to the manufacturer's instructions.
Preparation of DNA for transfection Cells (2 × 10 5 ) were transfected using lipofectamine (GibcoBRL) using a modification of the manufacturer's procedure. For each transfection, 5 g of plasmid DNA (in 10 l) was mixed with 90 l of serum-free medium (SFM), and this mixture was incubated for 45 min at room temperature with a mixture of 15 l lipofectamine (2 mg/ml) and 85 l SFM. Subsequently, the DNA-lipofectamine complex (200 l) was added to the cells as described below.
Transfection of DNA A stock culture of cells was trypsinised from a near confluent T25 flask (2 × 10 6 cells), resuspended in 12 ml of complete medium and divided equally between two sixwell multiwell tissue culture plates (Falcon). The following day (or when the cells were approximately 90% confluent) the culture medium was aspirated and the cell monolayer washed twice with pre-warmed sterile phosphate-buffered saline (PBS). Subsequently, 200 l of the DNA-Lipofectamine mixture was added to each of the 12 cell monolayers (2 × 10 5 cells) and mixed by gentle swirling. After 2-3 min, RPMI 1640 medium containing 5% FCS was added to a final volume of 1 ml. The cells were then incubated at 37°C for 5 h, after which time 1 ml of RPMI 1640 medium containing 15% FCS was added to give a final volume of 2 ml of medium containing 10% FCS, and the cells returned to the incubator. After 15 h the RPMI medium/DNA-lipofectamine mixture was replaced with 1 ml prewarmed complete tissue culture medium containing 10% FCS. The transfection efficiency in each experiment was determined by the same method in cells transfected with plasmids carrying the GFP ORF under the control of the strong constitutive CMV IE promoter (pCGFP). The mean percentage transfection efficiency of MCF-7 and U87-MG cells was 18.6 (standard deviation (s.d.) ± 4.3, n = 10) and 11.2 (s.d. ± 3.4, n = 10), respectively.
Radiation procedure
Transfected cells were irradiated as monolayers in sixwell plates at 37°C using a 60 Co ␥-ray source at a dose rate of 1.6 Gy per minute. In all experiments, monolayers of transfected cells were also mock-irradiated (controls), and subsequently treated identically to the irradiated monolayers of transfected cells. Following radiation treatment, the cells were reincubated and gene expression was assessed at various times later.
Analysis of GFP expression
Following irradiation and incubation at 37°C for 40 h the cells were analysed for radiation-induced gene expression by quantifying the number of GFP fluorescent cells in each sample. A 40 h time-point was selected as previous experiments (data not shown) had demonstrated a maximal level of GFP expression at this time using these experimental protocols. The cell monolayers were trypsinised to give a single cell suspension, washed three times with 1 ml of cold PBS by centrifugation and resuspension, and finally resuspended in 0.5 ml of PBS for FACS analysis. For each sample 1-10 × 10 5 cells were analysed on a Becton Dickinson FACScan flow cytometer with an excitation wavelength of 488 nm and FITC collection wavelength using a band-pass filter at 530 ± 15 nm. Dead cells were gated out of the analysed cohort by forward and side scatter. The level of GFP fluorescence in live cells was determined using the Becton Dickinson CellQuest program. Briefly, the distribution of GFP fluorescence in the cell population was plotted against the cell number on a 4-log linear scale. Cells that exhibited GFP fluorescence 100 times that of unirradiated-transfected cells were considered to show radiation-induced promoter activation resulting in GFP expression. The background level of expression for each sample was then calculated by dividing the percentage of GFP-positive cells in an irradiated sample by the corresponding value for the unirradiated sample transfected with the same plasmid. Presenting the data in this form compensates for the different levels of background fluorescence (ie nonradiation-induced expression of each construct) seen between the discrete plasmid constructs and between individual experiments. The level of radiation-induced gene expression was therefore expressed as the fold increase in percentage number of positive-GFP cells in each sample, compared with the corresponding unirradiated sample transfected with the same plasmid.
Growth inhibition MCF-7 cells were transfected with either pCon or pE4TK plasmids using the procedure described above. Twentyfour hours after transfection cells were re-seeded in 96 well flat-bottom microtitre cell culture plates (400 cells per well in 200 l) in complete medium with or without a 50 m ganciclovir (GCV). Three hours after plating the cells were irradiated. After 5 days incubation at 37°C the extent of cell growth was determined. Briefly, the culture medium was aspirated and replaced with 100 l of a 3 mg/ml solution of MTT [3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide] in PBS for 3 h, followed by 200 l of DMSO. The plates were agitated to ensure complete mixing, and scanned on a multiplate reader (Flow Ltd) at 530 nm and 690 nm. The mean plating efficiency (PE) value for each cell in the presence or absence of 50 m GCV was used to calculate individual measures of growth inhibition for each irradiated cell population in each experiment. A mean value of growth was then calculated from the two individual experiments.
